Tenax Therapeutics, Inc. (TENX)
| Market Cap | 705.36M +245.6% |
| Revenue (ttm) | n/a |
| Net Income | -57.91M |
| EPS | -1.41 |
| Shares Out | 58.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 775,404 |
| Open | 11.74 |
| Previous Close | 11.90 |
| Day's Range | 11.40 - 12.37 |
| 52-Week Range | 5.34 - 18.38 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 29.67 (+147.66%) |
| Earnings Date | May 12, 2026 |
About TENX
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for TENX stock is "Strong Buy." The 12-month stock price target is $29.67, which is an increase of 147.66% from the latest price.
News
Tenax Therapeutics reports Q1 EPS (35c), consensus (40c)
“We continued to make significant progress in advancing TNX-103, completing randomization of more than 230 patients in the Phase 3 LEVEL study at the end of the first quarter which…
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthene...
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company usin...
Tenax Therapeutics appoints Timothy Healey as chief commercial officer
Tenax Therapeutics (TENX) announced the appointment of Timothy Healey as chief commercial officer, effective immediately. Healey most recently served as chief commercial officer at Eversana Life Scien...
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience Mr. Healey is a seasoned pharmaceutical executive with a strong track record...
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” ...
Four new option listings on March 25th
New option listings for March 25th include Iperionx Ltd (ADR) (IPX), Strive, Inc. Variable Rate Series A Perpetual Preferred Stock (SATA), SunocoCorp LLC (SUNC), and Tenax Therapeutics (TENX). Publish...
Tenax Therapeutics files $300M mixed securities shelf
11:44 EDT Tenax Therapeutics (TENX) files $300M mixed securities shelf
Cantor starts Tenax at Overweight into Phase 3 readout
Cantor Fitzgerald initiated coverage of Tenax Therapeutics (TENX) with an Overweight rating and $35 price target The company has a pivotal Phase 3 readout of TNX-103 in heart failure with…
Tenax Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Tenax Therapeutics (TENX) with an Overweight rating and $35 price target
Tenax Therapeutics price target raised to $34 from $25 at Guggenheim
Guggenheim raised the firm’s price target on Tenax Therapeutics (TENX) to $34 from $25 and keeps a Buy rating on the shares. ahead of the Phase 3 LEVEL readout, the…
Tenax Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Gaurav Maini initiated coverage of Tenax Therapeutics (TENX) with an Outperform rating and $27 price target
Tenax Therapeutics Transcript: Leerink Global Healthcare Conference 2026
LEVEL trial completed enrollment ahead of schedule, with results expected in Q3 and strong patient retention. The global LEVEL-2 trial will expand reach and duration, while regulatory strategy focuses on robust safety and efficacy data. Cash runway and infrastructure support ongoing growth.
Tenax Therapeutics reports Q4 EPS (38c), consensus (41c)
“We are pleased to announce that we have recently achieved our randomization target of 230 patients in the Phase 3 LEVEL study. As we strive to make significant progress executing…
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients...
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company us...
Tenax Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Phase III trials for levosimendan in PH-HFpEF are progressing globally, with robust patient enrollment and strong statistical power. The drug shows significant clinical benefits, high patient compliance, and targets a large, underserved market with a differentiated oral therapy profile.
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company usi...
Tenax Therapeutics reports result of prespecified blinded sample size assessment
Tenax Therapeutics (TENX) announced that the prespecified Blinded Sample Size Re-estimation of LEVEL demonstrated the trial is powered at well over 90% to detect a 25 meter change in 6-minute…
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2...
Tenax Therapeutics price target raised to $25 from $14 at Guggenheim
Guggenheim raised the firm’s price target on Tenax Therapeutics (TENX) to $25 from $14 and keeps a Buy rating on the shares. The firm is reiterating Tenax as a Top…
Tenax Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
LEVEL phase III trial enrollment increased to 230, with results expected in the second half of next year. Both LEVEL 1 and LEVEL 2 use rigorous design, identical patient criteria, and a 3 mg oral dose, with LEVEL 2 expanding globally and extending to 26 weeks. Open-label extensions ensure patient access.
Tenax Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Phase III enrollment for PH-HFpEF is underway, with a second global trial starting soon and data expected in the second half of next year. The drug targets wedge pressure and has shown efficacy in prior studies, with a large addressable market and funding secured through 2027.
Tenax Therapeutics to Participate in Upcoming Investor Conferences
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical...
Tenax Therapeutics Transcript: KOL Event
Experts highlighted TNX-103's unique mechanism and strong clinical data in PH-HFpEF, emphasizing its differentiation from failed vasodilator and Relaxin trials. The oral formulation showed improved patient outcomes, robust patent protection, and potential as an add-on therapy.